• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ASP
Click for more information
0.07% $1.50

Smartshares Australian Property ETF Units - Charts / Financials

watchlist Created with Sketch. Add to my watchlist
refresh Created with Sketch. REFRESH
Day
Open $1.52   Day High $1.52   Day Low $1.50
Daily Volume 1747
Bids   Sellers
Number Price Volume   Number Price Volume
0 $1.49 7   0 $1.51 60009

Data source: Refinitiv

(20min delay)
Last
$1.50 		Change
0.001(0.07%) 		Mkt cap ! n/a
Open High Low Value Volume
$1.52 $1.52 $1.50 $2.634K 1.747K

Buyers (Bids)

No. Vol. Price($)
0 7 $1.49
 

Sellers (Offers)

Price($) Vol. No.
$1.51 60009 0
Last trade - 08.03am 02/10/2024 (20 minute delay) ?

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Maximus jumps 7% as it unveils latest gold drill hits at Eagles Nest; grades up to 15g/t Maximus Resources (ASX:MXR) has unveiled its latest drilling assay results at Eagles Nest, hitting gold downhole multiple assets.
PainChek close to finding out if FDA approves its flagship app for use in dementia care PainChek (ASX:PCK) has updated the market on the progress of its De Novo submission to the US FDA for its flagship app in aged care settings.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.